Predictive power of combined inflammatory markers and magnetic resonance imaging features for glioma grading using machine learning: a retrospective study.
Authors
Affiliations (5)
Affiliations (5)
- Department of Pediatrics, Tongji Hospital, Tongji University School of Medicine, Xincun Road No. 389, Shanghai, China.
- Department of Medical Imaging, Tongji Hospital, Tongji University School of Medicine, Xincun Road No. 389, Shanghai, China.
- Department of Neurosurgery, Tongji Hospital, Tongji University School of Medicine, Xincun Road No. 389, Shanghai, China.
- Department of Clinical Research Center, Tongji Hospital, Tongji University School of Medicine, Xincun Road No. 389, Shanghai, China.
- Department of Medical Imaging, Fudan University Affiliated Xuhui Hospital (Shanghai Xuhui Central Hospital), 366 Longchuan North Road, Xuhui District, Shanghai, 200031, China. [email protected].
Abstract
This study aimed to explore the potential of integrating magnetic resonance imaging (MRI) features with inflammatory markers to predict glioma grading using machine learning models. A total of 179 glioma patients were analyzed. The dataset was randomly split into a training set (75%) and an independent test set (25%) to test hyperparameter. To enhance reliability, five-fold cross-validation was also applied during the training phase. Key MRI features and inflammatory markers, including relative apparent diffusion coefficient (rADC), monocyte count, lymphocyte-to-CRP ratio (LCR) and hemoglobin-albumin-lymphocyte-platelet index (HALP), were extracted and used as inputs for multiple machine learning classifiers. Model performance was assessed using metrics such as area under the curve (AUC), accuracy, and F1 score. The support vector machine model exhibited superior predictive performance, achieving an AUC of 0.92 and an F1 score of 0.91, effectively distinguishing between high-grade and low-grade gliomas. The combination of MRI features and inflammatory markers, analyzed through machine learning models like SVM, provides some clues for refining glioma prognosis and guiding personalized treatment strategies. The online version contains supplementary material available at 10.1186/s12880-025-01946-0.